Beijing SL Pharmaceutical Co Ltd Asset Resilience Ratio

Latest as of March 2026: 8.77%

Beijing SL Pharmaceutical Co Ltd asset resilience ratio. Beijing SL Pharmaceutical Co Ltd (002038) has an Asset Resilience Ratio of 8.77% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Beijing SL Pharmaceutical Co Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

CN¥512.01 Million
≈ $74.92 Million USD Cash + Short-term Investments

Total Assets

CN¥5.84 Billion
≈ $854.10 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Beijing SL Pharmaceutical Co Ltd (2003–2025)

Asset resilience ratio of Beijing SL Pharmaceutical Co Ltd from 2003 to 2025. This chart shows how Beijing SL Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read Beijing SL Pharmaceutical Co Ltd debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Beijing SL Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Beijing SL Pharmaceutical Co Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥512.01 Million 8.77%
Total Liquid Assets CN¥512.01 Million 8.77%

Asset Resilience Insights

  • Limited Liquidity: Beijing SL Pharmaceutical Co Ltd maintains only 8.77% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Beijing SL Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Beijing SL Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
Drug Manufacturers - Specialty & Generic 0.16%
Sandoz Group AG
SW:SDZ
Drug Manufacturers - Specialty & Generic 7.89%
H Lundbeck A/S
CO:HLUN-B
Drug Manufacturers - Specialty & Generic -0.56%
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 5.50%
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
Drug Manufacturers - Specialty & Generic 47.16%
Kangmei Pharmaceutical Co Ltd
SHG:600518
Drug Manufacturers - Specialty & Generic 0.00%
Viyash Scientific Limited
NSE:SEQUENT
Drug Manufacturers - Specialty & Generic 0.08%
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
Drug Manufacturers - Specialty & Generic 1.81%

Beijing SL Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2003–2025)

Beijing SL Pharmaceutical Co Ltd asset resilience ratio by year from 2003 to 2025. The table below shows the annual Asset Resilience Ratio data for Beijing SL Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 8.22% CN¥498.95 Million
≈ $73.01 Million
CN¥6.07 Billion
≈ $888.54 Million
+0.17pp
2024-12-31 8.04% CN¥480.86 Million
≈ $70.36 Million
CN¥5.98 Billion
≈ $874.92 Million
-15.04pp
2023-12-31 23.08% CN¥1.45 Billion
≈ $212.06 Million
CN¥6.28 Billion
≈ $918.63 Million
+8.48pp
2022-12-31 14.61% CN¥858.27 Million
≈ $125.59 Million
CN¥5.88 Billion
≈ $859.82 Million
+11.79pp
2021-12-31 2.82% CN¥162.36 Million
≈ $23.76 Million
CN¥5.76 Billion
≈ $842.94 Million
-0.40pp
2020-12-31 3.22% CN¥173.81 Million
≈ $25.43 Million
CN¥5.39 Billion
≈ $789.43 Million
+0.53pp
2019-12-31 2.69% CN¥140.45 Million
≈ $20.55 Million
CN¥5.22 Billion
≈ $764.58 Million
+2.09pp
2018-12-31 0.59% CN¥29.65 Million
≈ $4.34 Million
CN¥4.99 Billion
≈ $729.94 Million
-0.94pp
2017-12-31 1.53% CN¥70.31 Million
≈ $10.29 Million
CN¥4.59 Billion
≈ $670.94 Million
+0.64pp
2016-12-31 0.89% CN¥36.48 Million
≈ $5.34 Million
CN¥4.08 Billion
≈ $597.22 Million
-0.14pp
2015-12-31 1.03% CN¥38.73 Million
≈ $5.67 Million
CN¥3.76 Billion
≈ $550.44 Million
+0.74pp
2014-12-31 0.29% CN¥9.47 Million
≈ $1.39 Million
CN¥3.32 Billion
≈ $485.68 Million
+0.05pp
2013-12-31 0.23% CN¥6.35 Million
≈ $929.58K
CN¥2.71 Billion
≈ $396.87 Million
-0.17pp
2012-12-31 0.40% CN¥8.91 Million
≈ $1.30 Million
CN¥2.22 Billion
≈ $324.37 Million
-0.10pp
2011-12-31 0.51% CN¥8.78 Million
≈ $1.29 Million
CN¥1.74 Billion
≈ $254.05 Million
-0.42pp
2010-12-31 0.93% CN¥11.57 Million
≈ $1.69 Million
CN¥1.25 Billion
≈ $182.71 Million
-1.22pp
2009-12-31 2.14% CN¥21.86 Million
≈ $3.20 Million
CN¥1.02 Billion
≈ $149.23 Million
+0.59pp
2008-12-31 1.55% CN¥12.22 Million
≈ $1.79 Million
CN¥788.52 Million
≈ $115.38 Million
-3.74pp
2007-12-31 5.29% CN¥31.05 Million
≈ $4.54 Million
CN¥586.63 Million
≈ $85.84 Million
+1.66pp
2005-12-31 3.64% CN¥14.76 Million
≈ $2.16 Million
CN¥405.91 Million
≈ $59.40 Million
-5.59pp
2003-12-31 9.22% CN¥14.00 Million
≈ $2.05 Million
CN¥151.83 Million
≈ $22.22 Million
--
pp = percentage points

About Beijing SL Pharmaceutical Co Ltd

SHE:002038 China Drug Manufacturers - Specialty & Generic
Market Cap
$774.22 Million
CN¥5.29 Billion CNY
Market Cap Rank
#9745 Global
#2466 in China
Share Price
CN¥5.15
Change (1 day)
+1.18%
52-Week Range
CN¥4.98 - CN¥8.98
All Time High
CN¥10151.79
About

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People's Republic of China and internationally. The company's finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; paclitaxel injection; docetaxel injection; thymopentin; vinorelbine tartrate injection; hydroxyl-camptothec… Read more